Document:

EX-10.15 1st Amendment to UPenn License Agreement

 

EXHIBIT 10.15

First Amendment to the License Agreement

between the

The Trustees of the University of Pennsylvania and Acuity Pharmaceuticals, Inc.

     This first amendment (this “First Amendment”) is made by and between Acuity
Pharmaceuticals Inc., a corporation organized under the laws of the State of Delaware and with
offices located at the Port of Technology, 3701 Market Street, Philadelphia, PA 19104 (“Company”),
and the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with
offices located at 3160 Chestnut Street, Suite 200, Philadelphia PA 19104 (“Penn”). This Amendment
is effective on 1 August 2003.

BACKGROUND

	 	A.	 	Penn and Company entered into an exclusive license agreement (the “Original
Agreement”),
pertaining to Penn Dockets P2928, P2974, P3009, P3069, P3075, P3087, and P3114 for
technology related to RNA interference developed by Dr. Michael Tolentino, Mr. Samuel
Reich,
and Dr. Enrico M. Surace of Penn’s School of Medicine, Department of Ophthalmology and
having an effective date of March 31, 2003;

	 	B.	 	Penn and Company have now reached an agreement to amend certain terms and
to include
additional technologies, which are expressed in this First Amendment; and

	 	C.	 	It is the intent of both parties to execute this First Amendment. The
Original Agreement as
amended by this First Amendment will be referred to as the “Agreement”.

     NOW THEREFORE, in consideration of the promises and covenants contained in this
First Amendment and intending to be legally bound, the parties agree to:

	 	1.	 	Unless otherwise defined, the definitions used in this First Amendment
are the same as those used in the Original Agreement. No other meanings are
implied.

	 	2.	 	To Exhibit A of the Original Agreement, the following dockets shall be added:

	 	 	 	P3158: RNAi Therapy for Glaucoma
	 
	 	 	 	P3159: Anti-HSV RNAi Therapy for Herpes Infection
	 
	 	 	 	P3183: Combined Therapy for AMD or Diabetic Retinopathy (Cand5 or Another
Anti-Angiogenic siRNA)

	 	3.	 	Section 2.3 of the Original Agreement is deleted in its
entirety and replaced by the
following:

PENN/ACUITY

Amendment for adding additional dockets to the Acuity License

Effective Date: 1 August 2003

 

 

2.3. Diligence Events. The Company will use commercially
reasonable efforts to achieve each of the diligence events by the
applicable completion date listed in the table below for the first
product to be commercialized by the Company pursuant to this Agreement.

	 	 	 
	DILIGENCE EVENT	 	COMPLETION DATE
	Delivery to Penn of a preliminary business plan

	 	June 30, 2003
	Raising at least an aggregate of $5 Million in equity
investment capital by Company from qualified investors

	 	December 31, 2004
	Filing of IND for first Licensed Product

	 	December 31, 2005
	Initiation
of Phase II clinical trials for first Licensed Product

	 	December 31, 2007
	Initiation
of Phase III clinical trials for first Licensed Product

	 	December 31, 2010
	First commercial Sale of first Licensed Product

	 	December 31, 2013

	 	4.	 	No other terms of the Original Agreement are modified by this First Amendment.
The Original Agreement and this First Amendment are the entire agreement between
the parties with respect to the subject matter of the Agreement as so amended.

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to
be executed by their duly authorized representatives.

	 	 	 	 	 	 	 	 
	THE TRUSTEES OF THE

UNIVERSITY OF PENNSYLVANIA

 	 	ACUITY PHARMACEUTICALS, INC.

 	 
	By:  	/s/
Louis P. Berneman, Ed. D
 	 	By:  	/s/
Dale R. Pfost, Ph.D.
 	 
	 	Louis P. Berneman, Ed. D	 	 	Dale R. Pfost, Ph.D. 	 
	 	Managing Director

Center for Technology Transfer	 	 	President and CEO 	 
	Date: 	11/19/03	 	Date: 	19 Nov 03	 
	 

PENN/ACUITY

Amendment for adding additional dockets to the Acuity
License
 Effective Date: 1 August 2003EX-10.16 1st Amendment to UPenn License Agreement

 

EXHIBIT 10.16

First
Amendment to the License Agreement

between the

The Trustees of the University of Pennsylvania and Acuity Pharmaceuticals, Inc.

     This first amendment (this “First Amendment”) is made by and between Acuity
Pharmaceuticals Inc. a corporation organized under the laws of the State of Delaware and with
offices located at the Port of Technology, 3701 Market Street Philadelphia, PA 19104 (“Company”),
and the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with
offices located at 3160 Chestnut Street, Suite 200, Philadelphia PA 19104 (“ Penn”). This Amendment
is effective on 1 August 2003.

BACKGROUND

	 	A.	 	Penn and Company entered into an exclusive license agreement (the “Original Agreement”),
pertaining to Penn Docket N2427 for technology related to RNA interference developed by
Dr. Alan Gewirtz of Penn’s School of Medicine, Department of Medicine, and having an
effective date of March 31, 2003;
	 
	 	B.	 	Penn and Company have now reached an agreement to amend certain terms, which
are expressed in this First Amendment; and
	 
	 	C.	 	It is the intent of both parties to execute this First Amendment. The
Original Agreement as amended by the First Amendment will be referred to as the “Agreement”.

     NOW
THEREFORE, in consideration of the promises and covenants contained in this First
Amendment and intending to be legally bound, the parties agree to:

	 	1.	 	Unless otherwise defined, the definitions used in this First
Amendment are the same as those used in the Original Amendment. No other
meanings are implied.
	 
	 	2.	 	Section 2.3 of the Original Agreement is deleted in its
entirety and replaced by the following:

                    2.3. Diligence Events.

     (a) The Company will use commercially reasonable efforts to achieve,
or cause to be achieved, each of lhe diligence events by the applicable
completion date listed in the table below for the first product to be
commercialized by the Company pursuant to this Agreement.

	 	 	 
	DILIGENCE EVENT	 	COMPLETION DATE
	Filing of IND for first Licensed Product

	 	December 31, 2005
	Initiation of Phase II clinical trials for first
Licensed Product

	 	December 31, 2007
	Initiation of Phase III clinical trials for first
Licensed Product

	 	December 31, 2010
	First commercial Sale of first Licensed Product

	 	December 31, 2013

PENN/ACUITY

Diligence Amendment to the Gewirtz Technology License

Effective Date: 1 August 2003

 

 

     (b) The Company will use commercially reasonable efforts to; (i)
deliver to Penn a preliminary business plan by June 30, 2003 and (ii)
raise at least an aggregate of $5 Million in equity investment
capital from qualified investors by December 31, 2004.

	 	3.	 	No other terms of the Original Agreement are modified by this First
Amendment. The Original Agreement and this First Amendment are the entire
agreement between the parties with respect to the subject matter of she
Agreement as so amended.

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to
the Original Agreement to be executed by their duly authorized representatives.

	 	 	 	 	 	 	 	 
	THE TRUSTEES OF THE

UNIVERSITY OF PENNSYLVANIA

 	 	ACUITY PHARMACEUTICALS, INC.

 	 
	By:  	/s/
Louis P. Berneman, Ed. D
 	 	By:  	/s/
Dale R. Pfost, Ph.D.
 	 
	 	Louis P. Berneman, Ed. D	 	 	Dale R. Pfost, Ph.D. 	 
	 	Managing Director

Center for Technology Transfer	 	 	President and CEO 	 
	Date: 	11/18/03	 	Date: 	19 Nov 03	 
	 

PENN/ACUITY

Diligence Amendment to the Gewirtz Technology License

Effective Date: 1 August 2003EX-10.17 Amended Restated Subordination Agreement

 

EXHIBIT 10.17

AMENDED AND RESTATED SUBORDINATION AGREEMENT

     AMENDED AND RESTATED SUBORDINATION AGREEMENT (this “Agreement”), dated as of March 27, 2007,
by and among The Frost Group, LLC, a Florida limited liability company (“Frost LLC” or the “Junior
Creditor”), Horizon Technology Funding Company LLC (the “Senior Creditor”) and Acuity LLC, a
Delaware limited liability company formerly known as e-Acquisition Company II-B, LLC (“Acuity””),
and eXegenics Inc., a Delaware corporation (“eXegenics” and with Acuity, the “Borrowers”).

     WHEREAS, Acuity Pharmaceuticals, Inc. (“Old Acuity”) borrowed funds from the Junior Creditor
pursuant to the terms of that certain Subordinated Note and Security Agreement dated as of January
11, 2007, by Old Acuity to Frost LLC and that certain Master Agreement dated as of January 11, 2007
by and between Old Acuity, Frost LLC and Froptix Corporation, a Florida corporation and granted a
security interest in all of Old Acuity assets and property as set forth in the Note and Security
Agreement;

     WHEREAS, Old Acuity has borrowed funds from the Senior Creditor pursuant to the terms of that
certain Venture Loan and Security Agreement, dated as of September 14, 2005, by and between Old
Acuity and the Senior Creditor and the Secured Promissory Note issued to Senior Creditor by Old
Acuity on September 14, 2005 and granted Senior Creditor a security interest in all of Old Acuity’s
assets and property as set forth in the Senior Debt Documents;

     WHEREAS, on March 27, 2007, Old Acuity, Froptix Corporation, eXegenics, Acuity and
e-Acquisition Company I-A, LLC entered into a Merger Agreement and Plan of Reorganization (the
“Merger Agreement”), pursuant to which Old Acuity was merged with and into Acuity, with Acuity
surviving the merger as a wholly-owned subsidiary of eXegenics (the “Acuity Merger”);

     WHEREAS, concurrently with the execution of this Agreement, Acuity and eXegenics entered into
an Amended and Restated Venture Loan and Security Agreement (the “Senior Loan Agreement”), dated as
of March 27, 2007 by and between Acuity, eXegenics and the Senior Creditor and the Secured
Promissory Note issued to Senior Creditor by Acuity and eXegenics on March 27, 2007 (with the
Senior Loan Agreement, the “Senior Debt Documents”) and granted Senior Creditor a security interest
(the “Senior Security Interest”) in all of eXegenics’ and Acuity’s assets and property as set forth
in the Senior Debt Documents;

     WHEREAS, concurrently with the execution of this Agreement, eXegenics, Acuity and the Junior
Creditor are entering into that certain Amended and Restated Subordinated Note and Security
Agreement dated as of March 27, 2007, (the “Note and Security Agreement”) and that certain Credit
Agreement dated as of March 27, 2007 (the “Credit Agreement” and, collectively with the Note and
Security Agreement, the “Junior Debt Documents”), and granted a security interest (the “Junior
Security Interest”) in all of eXegenics’ assets and property as set forth in the Note and Security
Agreement;

 

 

     NOW, THEREFORE, in consideration of the mutual promises, representations, warranties,
covenants and conditions set forth in this Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

     1. Subordination of Security Interest. The Junior Creditor hereby subordinates its
Junior Security Interest to and in favor of the Senior Security Interest. Further, notwithstanding
the respective dates of attachment or perfection of the Junior Security Interest and the Senior
Security Interest, the Senior Security Interest shall at all times be prior and superior to the
Junior Security Interest.

     2. Payment Obligations. All Obligations (as defined in the Credit Agreement) of the
Borrowers to Junior Creditor under the Junior Debt Documents (the “Junior Obligations”) are
subordinated in right of payment to all payment obligations under the Senior Loan Agreement (the
“Senior Obligations”). Nothing herein shall be deemed to subordinate, waive or restrict the
performance of the obligations of eXegenics to issue capital stock of eXegenics upon exercise or
conversion of any warrants or notes issued at any time by eXegenics to the Junior Creditor or the
other obligations of eXegenics to Junior Creditor pursuant to the Credit Agreement or Merger
Agreement that are unrelated to the Junior Obligations. Except as set forth herein, any payment of
any amounts or other consideration by eXegenics to Junior Creditor in respect of the Junior
Obligations or otherwise pursuant to the provisions of the Credit Agreement relating to such Junior
Obligations shall be restricted hereby.

     3. Covenants. Subject to and except as set forth in Section 4 below, the Junior
Creditor will not: (a) demand or receive from either of the Borrowers (and neither of the Borrowers
will pay to the Junior Creditor) all or any part of the Junior Obligations, by way of payment,
prepayment, setoff, lawsuit or otherwise; (b) exercise any right or remedy, or take any enforcement
action regarding any property or assets of either of the Borrowers; or (c) commence, or cause to be
commenced, prosecute or participate in any administrative, legal or equitable action against either
of the Borrowers or the Collateral (as defined in the Senior Loan Agreement), provided that,
notwithstanding the foregoing, the Junior Creditors shall be permitted to demand performance of the
Junior Obligations or commence action against the Borrowers to the extent necessary to preserve
their rights against the Borrowers under applicable law but it shall not be permitted to receive
payment from the Borrowers or foreclose on any Collateral until such time as the Senior Obligations
have been paid in full. The Borrowers expressly agrees that they shall not assert as a defense to
the Junior Obligations, the passage of time, estoppel, laches or any statute of limitations to the
extent that the exercise of any rights or remedies by the Junior Creditor was precluded by this
Agreement.

     4. Application of Payments to the Junior Creditor. The Junior Creditor shall promptly
deliver to the Senior Creditor in the form received (except for endorsement or assignment by the
Junior Creditor where required by the Senior Creditor) for application to the Senior Obligations
any payment, distribution, security or proceeds received by the Junior Creditor with respect to the
Junior Obligations other than in accordance with this Agreement,

-2-

 

including without limitation Section 2. Notwithstanding anything to the contrary in this
Agreement, under applicable law or otherwise, the Junior Creditor agrees that it shall not directly
or indirectly contest the validity, enforceability or priority of any lien securing the Senior
Obligations.

     5. Enforcement of Obligations. In the event of either of the Borrowers’ insolvency,
reorganization or any case or proceeding under any bankruptcy or insolvency law or laws relating to
the relief of debtors, these provisions shall remain in full force and effect, and the Senior
Obligations shall be paid in full before any payment is made with respect to the Junior
Obligations. Further, notwithstanding anything to the contrary contained herein, in the event the
Junior Creditor exercises rights and remedies against either of the Borrowers, the Junior Creditor
shall remit the proceeds of any such enforcement actions to the Senior Creditor until all Senior
Obligations are paid in full.

     6. Appointment. Until the Senior Obligations are fully paid in cash, the Junior
Creditor irrevocably appoints the Senior Creditor as the Junior Creditor’s attorney in fact, and
grants to the Senior Creditor a power of attorney with full power of substitution, in the name of
the Junior Creditor or in the name of the Senior Creditor, for the use and benefit of the Senior
Creditor, without notice to the Junior Creditor, in any bankruptcy, insolvency or similar
proceeding involving either of the Borrowers to file the appropriate claim or claims in respect of
the Junior Obligations on behalf of the Junior Creditor if the Junior Creditor does not do so prior
to 15 days before the expiration of the time to file claims in such proceeding.

     7. Financing Statements. By the execution of this Agreement, the Junior Creditor
hereby authorizes the Senior Creditor to amend any financing statements filed by the Junior
Creditor or its agent on its behalf against the Borrowers as follows: “In accordance with a certain
Subordination Agreement by and among the Secured Party, the Debtor and Horizon Technology Funding
Borrower LLC, the Secured Party has subordinated any security interest or lien that Secured Party
may have in any property of the Debtor to the security interest of Horizon Technology Funding
Borrower LLC in all assets of the Debtor, notwithstanding the respective dates of attachment or
perfection of the security interest of the Secured Party and Horizon Technology Funding Borrower
LLC.”

     8. Amendment to Junior Debt Documents. No amendment of the documents evidencing or
relating to the Junior Obligations shall directly or indirectly modify the provisions of this
Agreement in any manner which might terminate or impair the subordination of the Junior Obligations
or the subordination of the Junior Security Interest that the Junior Creditor may have in any
property of the Borrowers.

     9. Disgorgement. If, at any time after payment in full of the Senior Obligations any
payments of the Senior Obligations must be disgorged by the Senior Creditor for any reason
(including, without limitation, the bankruptcy of either of the Borrowers) and Junior Creditor
shall have received any payments with respect to the Junior Obligations, this Agreement and the
relative rights and priorities set forth herein shall be reinstated as to all such disgorged
payments as though such payments had not been made and the Junior Creditor shall immediately pay
over to the Senior Creditor for application to the Senior Obligations, all payments received with

-3-

 

respect to the Junior Obligations to the extent that such payments would have been prohibited
hereunder. At any time and from time to time, without notice to the Junior Creditor, the Senior
Creditor may take such actions with respect to the Senior Obligations as the Senior Creditor, in
its sole discretion, may deem appropriate, including, without limitation, extending the time of
payment, increasing applicable interest rates, renewing, compromising or otherwise amending the
terms of any documents affecting the Senior Obligations and any collateral securing the Senior
Obligations, and enforcing or failing to enforce any rights against either of the Borrowers or any
other person. No such action or inaction shall impair or otherwise affect the Senior Creditor’s
rights hereunder.

     10. Term. The subordinations, agreements and priorities set forth hereinabove shall
remain in full force and effect regardless of whether any party hereto in the future seeks to
rescind, amend, terminate or reform, by litigation or otherwise, its respective agreements with
either of the Borrowers. This Agreement is effective from the date hereof until the earlier of (i)
payment in full of the Senior Obligations and (ii) release by the Junior Creditor of the Junior
Security Interest.

     11. Successors and Assigns. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties.

     12. Entire Agreement. This Agreement and the schedules referred to herein constitute
the entire agreement among the parties and supersede all prior communications, representations,
understandings and agreements of the parties with respect to the subject matter hereof. All
schedules hereto are hereby incorporated herein by reference. Nothing in this Agreement, express
or implied, is intended to confer upon any third party any rights, remedies, obligations or
liabilities under or by reason of this Agreement.

     13. General Interpretation. The terms of this Agreement have been negotiated by the
parties hereto and the language used in this Agreement shall be deemed to be the language chosen by
the parties hereto to express their mutual intent. This Agreement shall be construed without
regard to any presumption or rule requiring construction against the party causing such instrument
or any portion thereof to be drafted, or in favor of the party receiving a particular benefit under
this Agreement. No rule of strict construction will be applied against any person or entity.

     14. CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER. THIS AGREEMENT SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO
PRINCIPLES OF CONFLICTS OF LAW. EACH OF SENIOR CREDITOR AND JUNIOR CREDITOR HEREBY SUBMITS TO THE
NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF DELAWARE.
SENIOR CREDITOR AND JUNIOR CREDITOR HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY
CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS
CONTEMPLATED

-4-

 

HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON
LAW OR STATUTORY CLAIMS.

     15. Counterparts; Facsimile Signatures. This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original, and all of which together shall
constitute one and the same document. This Agreement may be executed by facsimile signatures.

     16. Section Headings. The section headings are for the convenience of the parties and
in no way alter, modify, amend, limit or restrict the contractual obligations of the parties.

     17. Notices. All notices required or permitted under this Agreement shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be
notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the
recipient, if not, then on the next business day, (c) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business
day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. All such communications shall be sent to the Senior Creditor
at 76 Batterson Park Road, Farmington, CT 06032, Attention: Legal Department and to the Junior
Creditor at 4400 Biscayne Blvd., 15th Floor, Miami, FL 33137, Attention: Steve Rubin,
Esq., or at such other address as the Senior Creditor or the Junior Creditor may designate by ten
(10) days advance written notice to the other parties hereto.

     18. Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), with the written consent of the Senior
Creditor and the Junior Creditor.

     19. Pronouns. Whenever the context may require, any pronouns used in this Agreement
shall include the corresponding masculine, feminine or neutral forms, and the singular form of
nouns and pronouns shall include the plural, and vice versa.

     20. Severability. Wherever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement.

[Signatures on following pages]

-5-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered by their proper and duly authorized officers as of the date first written above.

	 	 	 	 	 
	 	HORIZON TECHNOLOGY FUNDING COMPANY LLC
 	 
	 	By:  	                                                     Horizon Technology Finance, LLC, its sole member
 	 
	 	 	 	 
	 	 	 	 
	 
	 	 	 
	 	By:  	                                                     /s/ Gerald A. Michaud
 	 
	 	 	Name:  	Gerald A. Michaud 	 
	 	 	Title:  	Managing Member 	 
	 
	 	THE FROST GROUP, LLC

 	 
	 	By:  	/s/ Steven D. Rubin
 	 
	 	 	Name:  	Steven D. Rubin 	 
	 	 	Title:  	Vice President 	 
	 
	 	ACUITY PHARMACEUTICALS, LLC.

 	 
	 	By:  	/s/ Dale R. Pfost
 	 
	 	 	Name:  	Dale R. Pfost 	 
	 	 	Title:  	President 	 
	 
	 	EXEGENICS INC.

 	 
	 	By:  	/s/ John Paganelli
 	 
	 	 	Name:  	John Paganelli 	 
	 	 	Title:  	Interim Chief Executive Officer 	 
	 

-6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]